Treatment with ligelizumab achieves over forty percent higher complete response rate in chronic spontaneous urticaria patients originally treated with omalizumab
ALLERGY(2020)
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined